{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:25:47Z","timestamp":1788387947291,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,18]],"date-time":"2020-01-18T00:00:00Z","timestamp":1579305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002242","name":"Nathan's Battle","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.oret.2020.01.011","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T20:41:30Z","timestamp":1579639290000},"page":"728-736","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Symmetric Age Association of Retinal Degeneration in Patients with CLN2-Associated Batten Disease"],"prefix":"10.1016","volume":"4","author":[{"given":"Kyle D.","family":"Kovacs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9367-7349","authenticated-orcid":false,"given":"Samir","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Orlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7103-924X","authenticated-orcid":false,"given":"Keunpyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherri","family":"Van Everen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Conner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolan","family":"Sondhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Kaminsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald J.","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald G.","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szil\u00e1rd","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2020.01.011_bib1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/ajmg.1320570206","article-title":"Neuronal ceroid-lipofuscinoses in Italy: an epidemiological study","volume":"57","author":"Cardona","year":"1995","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.oret.2020.01.011_bib2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1469-8749.1974.tb04183.x","article-title":"Infantile type of so-called neuronal ceroid-lipofuscinosis","volume":"16","author":"Santavuori","year":"1974","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.oret.2020.01.011_bib3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1399-0004.2008.01054.x","article-title":"The clinical and genetic epidemiology of neuronal ceroid lipofuscinosis in Newfoundland","volume":"74","author":"Moore","year":"2008","journal-title":"Clin Genet"},{"key":"10.1016\/j.oret.2020.01.011_bib4","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pediatrneurol.2017.01.034","article-title":"Management strategies for CLN2 disease","volume":"69","author":"Williams","year":"2017","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.oret.2020.01.011_bib5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40263-019-00620-8","article-title":"Current and emerging treatment strategies for neuronal ceroid lipofuscinoses","volume":"33","author":"Kohlsch\u00fctter","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.oret.2020.01.011_bib6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1212\/WNL.0b013e31825f0547","article-title":"New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses","volume":"79","author":"Williams","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.oret.2020.01.011_bib7","series-title":"The Neuronal Ceroid Lipofuscinoses (Batten Disease)","author":"Mole","year":"2011"},{"issue":"10 Pt B","key":"10.1016\/j.oret.2020.01.011_bib8","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.bbadis.2015.05.011","article-title":"Genetics of the neuronal ceroid lipofuscinoses (Batten disease)","volume":"1852","author":"Mole","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.oret.2020.01.011_bib9","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0167-4838(98)00238-6","article-title":"Tripeptidyl-peptidase I is apparently the CLN2 protein absent in classical late-infantile neuronal ceroid lipofuscinosis","volume":"1429","author":"Rawlings","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.oret.2020.01.011_bib10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0014-5793(98)01683-4","article-title":"Classical late infantile neuronal ceroid lipofuscinosis fibroblasts are deficient in lysosomal tripeptidyl peptidase I","volume":"443","author":"Vines","year":"1999","journal-title":"FEBS Lett"},{"key":"10.1016\/j.oret.2020.01.011_bib11","series-title":"The Neuronal Ceroid Lipofuscinosis (Batten Disease)","first-page":"37","article-title":"Classic late infantile NCL","author":"Williams","year":"1999"},{"key":"10.1016\/j.oret.2020.01.011_bib12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ajmg.10660","article-title":"Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations","volume":"112","author":"Steinfeld","year":"2002","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.oret.2020.01.011_bib13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1212\/01.wnl.0000267885.47092.40","article-title":"Neurological deterioration in late infantile neuronal ceroid lipofuscinosis","volume":"69","author":"Worgall","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.oret.2020.01.011_bib14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ymgme.2004.06.019","article-title":"Electroretinographic and clinicopathologic correlations of retinal dysfunction in infantile neuronal ceroid lipofuscinosis (infantile Batten disease)","volume":"83","author":"Weleber","year":"2004","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.oret.2020.01.011_bib15","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/bjo.2006.091637","article-title":"Batten disease: features to facilitate early diagnosis","volume":"90","author":"Collins","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2020.01.011_bib16","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3109\/13816810903258829","article-title":"Autofluorescence and infrared retinal imaging in patients and obligate carriers with neuronal ceroid lipofuscinosis","volume":"30","author":"Kelly","year":"2009","journal-title":"Ophthal Genet"},{"issue":"Pt 3b","key":"10.1016\/j.oret.2020.01.011_bib17","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/eye.1998.148","article-title":"The dystrophic retina in multisystem disorders: the electroretinogram in neuronal ceroid lipofuscinoses","volume":"12","author":"Weleber","year":"1998","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2020.01.011_bib18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/IAE.0b013e31819b0542","article-title":"Funduscopic and angiographic appearance in the neuronal ceroid lipofuscinoses","volume":"29","author":"Hainsworth","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.oret.2020.01.011_bib19","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/humu.22292","article-title":"Autosomal recessive spinocerebellar ataxia 7 (SCAR7) is caused by variants in TPP1, the gene involved in classic late-infantile neuronal ceroid lipofuscinosis 2 disease (CLN2 disease)","volume":"34","author":"Sun","year":"2013","journal-title":"Hum Mutat"},{"key":"10.1016\/j.oret.2020.01.011_bib20","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.gene.2012.12.058","article-title":"Neuronal ceroid lipofuscinosis type CLN2: a new rationale for the construction of phenotypic subgroups based on a survey of 25 cases in South America","volume":"516","author":"Kohan","year":"2013","journal-title":"Gene"},{"key":"10.1016\/j.oret.2020.01.011_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073128","article-title":"Spectrum of ocular manifestations in CLN2-associated batten (Jansky-Bielschowsky) disease correlate with advancing age and deteriorating neurological function","volume":"8","author":"Orlin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.oret.2020.01.011_bib22","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of intraventricular cerliponase alfa for CLN2 disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2020.01.011_bib23","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/jnr.23423","article-title":"Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease)","volume":"92","author":"Katz","year":"2014","journal-title":"J\u00a0Neurosci Res"},{"key":"10.1016\/j.oret.2020.01.011_bib24","series-title":"Clinical Review Report: Cerliponase Alfa (Brineura): Biomarin Pharmaceutical (Canada) Inc: Indication: for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency [Internet]","year":"2019"},{"key":"10.1016\/j.oret.2020.01.011_bib25","series-title":"CADTH Common Drug Review. CADTH Canadian Drug Expert Committee Recommendation: Cerliponase Alfa","year":"2019"},{"key":"10.1016\/j.oret.2020.01.011_bib26","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/hum.2008.022","article-title":"Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA","volume":"19","author":"Worgall","year":"2008","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.oret.2020.01.011_bib27","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/14712598.2018.1492544","article-title":"Progress in gene and cell therapies for the neuronal ceroid lipofuscinoses","volume":"18","author":"Donsante","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.oret.2020.01.011_bib28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.exer.2014.06.008","article-title":"Enzyme replacement therapy delays pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis","volume":"125","author":"Whiting","year":"2014","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.oret.2020.01.011_bib29","doi-asserted-by":"crossref","first-page":"10347","DOI":"10.1038\/s41598-017-10473-0","article-title":"Retrospective analysis of structural disease progression in retinitis pigmentosa utilizing multimodal imaging","volume":"7","author":"Cabral","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.oret.2020.01.011_bib30","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.ajo.2015.06.032","article-title":"Multimodal imaging of central retinal disease progression in a 2-year mean follow-up of retinitis pigmentosa","volume":"160","author":"Sujirakul","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2020.01.011_bib31","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2352-4642(18)30179-2","article-title":"Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study","volume":"2","author":"Nickel","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.oret.2020.01.011_bib32","doi-asserted-by":"crossref","first-page":"6824","DOI":"10.1167\/iovs.16-20963","article-title":"Asymmetric inter-eye progression in Stargardt disease","volume":"57","author":"Lambertus","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2020.01.011_bib33","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(16)30371-3","article-title":"Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial","volume":"388","author":"Bennett","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2020.01.011_bib34","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","article-title":"Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial","volume":"374","author":"Maguire","year":"2009","journal-title":"Lancet"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653020300245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653020300245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:28:12Z","timestamp":1762853292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653020300245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S2468653020300245"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2020.01.011","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Symmetric Age Association of Retinal Degeneration in Patients with CLN2-Associated Batten Disease","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2020.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of OphthalmologyThis is an open access article under the CC BY license (<inter-ref xlink: href=http:\/\/creativecommons.org\/licenses\/by\/4.0\/>http:\/\/creativecommons.org\/licenses\/by\/4.0\/<\/inter-ref>).","name":"copyright","label":"Copyright"}]}}